Most hypertensive patients have additional cardiovascular risk factors. Therefore, as stressed in all recent guidelines from expert committees, an evaluation of all risk factors and an assessment of each patient's individual risk status is needed before deciding upon the need for therapy and the type of therapy to be given. In particular, attention must be directed at those risk factors that may be involved in the pathogenesis of hypertension: obesity, excessive sodium intake, physical inactivity, and stress. If active therapy is needed for established hypertension, all modifiable unhealthy lifestyles should be addressed along with appropriate drug therapy. Am J Hypertens 2001;14:221S-224S
T he overwhelming majority of hypertensive patients have one or more other major cardiovascular disease (CVD) risk factors. 1 Of all the hypertensive patients in the Framingham cohort, only 18% had no other major CVD risk factors. Looked at from another angle, only 4% of the hypertensives in the cohort would be classified into the lowest category of risk (group A) in the 1997 Joint National Committee report 2 and therefore in need only of lifestyle modifications as therapy. 3 The current guidelines from expert committees worldwide 2, 4, 5 emphasize the need to treat hypertension in the context of the entire cardiovascular risk profile. Both the level of blood pressure considered in need of active drug therapy and the specific choice of therapy are largely based upon the individual patient's overall risk status.
As stated in guidelines of the World Health Organization-International Society of Hypertension Guidelines for Management of Hypertension (WHO-ISH), "Decisions about the management of patients with hypertension should not be based on the level of blood pressure alone, but also on the presence of other risk factors, concomitant diseases such as diabetes, target-organ damage and cardiovascular or renal disease, as well as other aspects of the patient's personal, medical and social situation." 
The Metabolic Syndrome or The Deadly Quartet
In their table "Factors influencing prognosis," the WHO-ISH guidelines 4 provide an even more detailed and specific listing of the risk factors that need to be considered (Table 1 ) than are provided in either the JNC-6 report 2 or the report of the British Hypertension Society. 5 All of these reports provide simple ways to categorize each patient's relative risk status.
It is obvious that this list of risk factors includes the major components of what has been referred to as the metabolic syndrome X or the Deadly Quartet: hypertension, dyslipidemia (usually with high triglycerides and low HDL-cholesterol), glucose intolerance/diabetes mellitus, and obesity that is usually distributed in the upper body (visceral or abdominal). 6 These multiple risk factors may very well involve insulin resistance (Fig. 1) .
As obesity is growing rapidly in all industrially developed societies, this syndrome is becoming increasingly common and will be a major contributor to a virtual epidemic of microvascular and macrovascular disease unless it can be prevented.
The Need for Prevention
Regardless of the causal pathways, the need to prevent the development of hypertension and the frequently accompanying metabolic disturbances is obvious. The lack of definitive evidence that prevention is possible has been used as an excuse not to aggressively apply those preventive measures that logically should help. It may never be possible to document the ability of any maneuver to prevent hypertension in free-living human beings. In addition, evidence from animal models may not always be applicable to the human condition; but, along with considerable epidemiologic evidence, they give support to the value of certain maneuvers. These include: 1) prevention of obesity, 2) moderation of sodium intake, 3) maintenance of regular physical activity, and 4) reduction of stress.
In addition, provision of adequate potassium intake and moderation of alcohol intake of no more than 1 to 2 portions per day may offer additional benefits. In a world that is increasingly given to sloth, gluttony, and intimidation, these maneuvers may never be widely practiced, but the effort to help the entire population to follow them is clearly worthwhile. The ability to get almost half of American adult smokers to quit over the past 15 years is an affirmation of the value of broad-based preventive campaigns.
Only relatively short-term studies have been performed, none on a large enough population to prove the protective capacity of these maneuvers. Examples include the 30-month trial of sodium reduction and weight loss in the treatment of hypertension in older persons (the TONE trial) 7 and the long-term follow-up of the Trials of Hypertensive Prevention. 8 In both of these, reductions in the appearance of hypertension were noted despite only relatively small reductions in weight and sodium intake.
Because obesity is now, and will be even more in the future, the major factor leading to the metabolic syndrome, caloric restriction and increased physical activity must be encouraged. The need is greatest with children among whom obesity is most rapidly increasing, mainly because of physical inactivity. 9 Considering the increasingly hectic style of living throughout the world, the ability to significantly reduce stress in the overall population seems very unlikely. Even though stress is a likely contributor to the heightened sympathetic tone that may be an early feature of hypertension, 10 the ability to reduce stress except for brief intervals has not been documented. When stress reduction techniques have been used in short-term studies, mixed results on blood pressure have been noted.
11

Treatment After the Fact
Once present, hypertension and its accompanying additional risk factors must be treated. Fortunately, significant protection against heart attack, stroke, and heart failure by antihypertensive drug therapies has been documented, mostly in elderly patients 12 but in high-risk younger patients as well. 13 As impressive as these results are when compared with those of placebo, two nagging problems about treatment remain. One is the inability to maintain a sizable portion of patients (as many as half) on therapy, once it has been initiated. The other is the failure of therapies, as given in the recent past, to reduce morbidity and mortality to the levels seen in normotensive persons. 14 These problems are being addressed in multiple ways, including the following: 1) provision of agents that need to be taken only once a day to provide full 24-h coverage; 2) availability of agents that have fewer adverse effects; 3) individualization of therapy, using agents more likely to fit each patient's needs, based partly on age but more on the presence of concomitant conditions, some which may be made worse and others improved by the specific choices of therapy (Table 2 ); 4) recognition that simply starting therapy is not enough but rather that therapy must be increased to whatever magnitude is needed to reach the goal of therapy, a goal of Ͻ 140/90 mm Hg for most but even lower for such high risk patients as those with diabetes 15 ; and 5) appreciation of the critical need to address all the major risk factors that so often accompany hypertension. Additional benefits will likely be seen as each risk factor is addressed. For example, the correction of dyslipidemia has been shown to reduce blood pressure and left ventricular mass. 16 In conclusion, by appropriate provision of both lifestyle modifications and antihypertensive drug therapy, much better protection against hypertension-induced morbidity and mortality can be provided.
FIG. 1.
Overall schemes for the mechanisms by which obesity could promote diabetes, dyslipidemia, and hypertension via hyperinsulinemia. 
